Vanguard Capital Management
PCSA icon

Vanguard Capital Management’s Processa Pharmaceuticals PCSA Stock Holding History

Vanguard Capital Management’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4K Hold
12,729
– – ﹤0.01% 4003
2026
Q1 		$32.1K Buy
+12,729
New +$34.8K ﹤0.01% 3955

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management's PCSA Position: Q2 2026 in Review

Vanguard Capital Management held its Processa Pharmaceuticals (PCSA) position steady in Q2 2026 at 12,729 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4003.

Vanguard Capital Management first reported a position in PCSA in Q1 2026 and has held it in 2 quarters since. The position peaked at $32.1K in Q1 2026. 11 funds tracked by Wall St. Rank hold PCSA as of Q2 2026.

  • Vanguard Capital Management held 12,729 shares of Processa Pharmaceuticals worth $24.4K as of Q2 2026.
  • Vanguard Capital Management left its Processa Pharmaceuticals share count unchanged in Q2 2026.
  • Processa Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4003 holding.
  • Vanguard Capital Management first reported a position in Processa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Processa Pharmaceuticals position peaked at $32.1K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.